hivviralload.com Report : Visit Site

Technical data of the hivviralload.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host hivviralload.com. Currently, hosted in United States and its service provider is Squarespace .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called SSWS containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

blog about contact blog about contact search -- subscribe by rss blog rss top blog about contact blog written by: connect with us: twitter linkedin previous blog posts: “treat all” provides new hope as well as new challenges in the fight against hiv what the eib innovfin award means for cavidi and hiv management how you can help make viral load testing a reality this world aids day investment with impact: closing the hiv treatment gap world aids day 2013: halfway to zero viral load monitoring enters the mainstream time for a new gold standard in hiv viral load monitoring hiv viral load monitoring: from patient to public health issue could rt technology help close the eid gap? commentary on ”reverse innovation” ”getting to zero” will require more than funding to succeed advancements in technology lead to early hiv detection in kenya’s infants testing viral load just once a year could change the face of hiv a solution hiding right under our noses barack obama’s ambitious hiv plan inspires hope, but hope is only the first step nobel prize gives credit where it’s due…sort of world aids day 2008 – economic crisis raises significance of this year’s event the hiv subtype picture what sudden spikes in hiv viral load really mean the answers to your hiv viral load questions a viral load monitoring success story from zambia watch how hiv works global triage - food first or hiv first? the donor dilemma aids slang speaks volumes a taxi ride in lusaka thoughts on the international aids conference in mexico to tell or not to tell? talk to us at aids 2008 in mexico! universal action now the three biggest myths about viral load monitoring in resource-limited settings the difference between hiv viral load and cd4 tests three reasons viral load monitoring matters cnn raises awareness for viral load testing what’s a blog? oh, right, a blog… tags for this blog: africa (6) aids (13) aids 2008 mexico (4) art (3) arv (2) cavendish global health impact forum (1) cavidi (5) cd4 (3) comparison (1) compliance (1) current affairs (4) eib (1) eid (2) hiv monitoring info (11) hiv news (5) hiv viral load (12) nobel prize (1) patient (1) resource-limited settings (8) rt assay (3) science (2) world aids day (3) xvii international aids conference (1) aids (2) antiretroviral treatment (1) art (1) arvs (1) assays comparison (1) cavendish global (1) cavendish global health impact forum (1) cavidi (3) close hiv gap (1) dna pcr (1) doctors without borders (1) early infant diagnosis (2) eib (1) eid (1) european investment bank (1) exavir (2) getting to zero (1) gold standard (1) health care (1) hiv (4) hiv diagnostics (1) hiv monitoring (2) hiv viral load monitoring (5) hiv viral load video (1) infectious diseases innovation loan (1) innovfin (1) load zero foundattion (1) ministry of international development & cooperation (1) msf (1) mtct (1) pcr (1) public health issue (2) resource limited setting (1) reverse innovation (1) rt technology (2) treatment 2015 (1) unitaid (1) viral load monitoring (2) wad2014 (1) who (1) world aids day (3) ziva (1) blog index the journal that this archive was targeting has been deleted. please update your configuration. navigation links login monday nov 30 2015 “treat all” provides new hope as well as new challenges in the fight against hiv november 30, 2015 world aids day 2015 once again directs the public’s attention toward the ongoing hiv pandemic and the efforts to contain it. as the year draws to an end, we can see great progress over the past twelve months and a clear agenda for 2016. this past may, we learned that the start study , sponsored by unaids, was being prematurely concluded by study organizers because results were already so clear: data showed that those who received anti-retroviral therapy (art) immediately upon hiv diagnosis were 53% less likely to die during the trial or develop aids or a serious illness than those who waited for initiation of treatment. the start study addressed a point that had been widely debated by the hiv healthcare community for years. that debate was swiftly resolved when michel sidibé, executive director of unaids, concluded that, “every person living with hiv should have immediate access to life-saving antiretroviral therapy. delaying access to hiv treatment under any pretext is denying the right to health.” it didn’t take long for the world health organization (who) to act on the findings. in september of this year, the who updated its treatment guidelines to include a “treat all” provision. it recommends that everyone with hiv is provided art immediately after diagnosis. this is one of the most significant developments in the treatment of hiv over the last decade. michel sidibé explained that the policy change could help prevent 21 million aids-related deaths and 28 million new infections by 2030. of course, with the new who guidelines come new challenges for healthcare providers around the world. according to unaid’s estimates, 57% of hiv positive adults do not receive treatment today. based on that figure, the new who guidelines will mean proving art to an additional 21 million people globally. one of the greatest challenges in making “treat all” a reality is that the overwhelming majority of the untreated live in resource-limited settings. in developing nations around the world, healthcare organizations are working to find ways to increase access to art, as well as to the viral load monitoring required for proper administration of the life-saving drugs. i’m happy to report progress on that front as well. in september of this year, cavidi was selected by the european investment bank (eib) as a recipient of their infectious diseases innovation loan for 2015 . the focus of the loan is our ziva™ viral load monitoring system. viral load monitoring is an essential part of hiv treatment, but, until now, it has been difficult to administer in near-patient settings. ziva ™ changes that by providing a medium throughput, fully-automated viral load monitoring system purpose-built to meet the requirements of decentralized labs like those found in district hospitals across the developing world. its unique reverse transcriptase (rt) technology makes fully-automated gold-standard results possible for decentralized testing. the recognition of the eib is a great honor for cavidi, but an even bigger win for people infected with hiv around the world. while the €10 million loan is only part of the investment required to get ziva™ to market, it will go far to provide access to viral load monitoring sooner for millions living with hiv. all things considered, 2015 has been a pivotal year in the battle against hiv and cause for renewed optimism. the new who guidelines mark a significant shift in the global treatment mindset. the hiv treatment community has overcome great challenges to reach this point where “treat all” is the official policy moving forward. the financial and logistic challenges we now face to implement the policy are significant, yet dwarfed in comparison. addressing these new challenges will be our focus at cavidi for 2016 and beyond. post a comment wednesday sep 16 2015 what the eib innovfin award means for cavidi and hiv management september 16, 2015 speaking on behalf of the entire cavidi team, we are honored to be chosen by the european investment bank (eib) as recipient of their infectious diseases innovation loan for 2015 . this €10 million award will provide a substantial portion of the investment required to bring ziva™ to market in 2016. just as importantly, it underscores the importance of the groundbreaking work cavidi is doing in the area of hiv management. viral load monitoring is an essential part of hiv treatment, but it has always been difficult to administer in near-patient settings. ziva™ changes that. building off of cavidi’s proprietary reverse transcriptase (rt) technology, we have designed ziva™ as a medium throughput, fully-automated viral load monitoring system. it is purpose-built to m

URL analysis for hivviralload.com

http://www.hivviralload.com/blog/2012/7/22/could-rt-technology-help-close-the-eid-gap.html#comments
http://www.hivviralload.com/blog/2009/3/19/a-solution-hiding-right-under-our-noses.html
http://www.hivviralload.com/blog/2012/4/18/commentary-on-reverse-innovation.html
http://www.hivviralload.com/blog/2008/7/21/universal-action-now.html
http://www.hivviralload.com/blog/2013/11/28/world-aids-day-2013-halfway-to-zero.html
http://www.hivviralload.com/blog/tag/hiv-viral-load-monitoring
http://www.hivviralload.com/blog/2015/9/16/what-the-eib-innovfin-award-means-for-cavidi-and-hiv-managem.html#comments
http://www.hivviralload.com/blog/tag/unitaid
http://www.hivviralload.com/blog/2008/12/10/nobel-prize-gives-credit-where-its-duesort-of.html
http://www.hivviralload.com/blog/tag/early-infant-diagnosis
http://www.hivviralload.com/contact/
http://www.hivviralload.com/blog/2012/7/22/could-rt-technology-help-close-the-eid-gap.html
http://www.hivviralload.com/blog/2008/7/17/the-three-biggest-myths-about-viral-load-monitoring-in-resou.html
http://www.hivviralload.com/blog/?currentpage=4
http://www.hivviralload.com/blog/tag/cavidi

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: HIVVIRALLOAD.COM
Registry Domain ID: 1509846324_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ascio.com
Registrar URL: http://www.ascio.com
Updated Date: 2018-06-19T06:05:42Z
Creation Date: 2008-07-23T08:29:04Z
Registry Expiry Date: 2019-07-23T08:29:04Z
Registrar: Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Registrar IANA ID: 106
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +442070159370
Domain Status: ok https://icann.org/epp#ok
Name Server: NS3.LOOPIA.SE
Name Server: NS4.LOOPIA.SE
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-08-15T02:03:50Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =hivviralload.com

  PORT 43

  TYPE domain

DOMAIN

  NAME hivviralload.com

  CHANGED 2018-06-19

  CREATED 2008-07-23

STATUS
ok https://icann.org/epp#ok

NSERVER

  NS3.LOOPIA.SE 93.188.0.21

  NS4.LOOPIA.SE 93.188.0.20

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .